Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea.
Cellvertics Co. Ltd., Seoul, Korea.
Endocrinol Metab (Seoul). 2022 Apr;37(2):221-232. doi: 10.3803/EnM.2021.1237. Epub 2022 Mar 23.
Obesity, the prevalence of which is increasing due to the lack of exercise and increased consumption of Westernized diets, induces various complications, including ophthalmic diseases. For example, obesity is involved in the onset of cataracts.
To clarify the effects and mechanisms of midodrine, an α1-adrenergic receptor agonist, in cataracts induced by obesity, we conducted various analytic experiments in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a rat model of obesity.
Midodrine prevented cataract occurrence and improved lens clearance in OLETF rats. In the lenses of OLETF rats treated with midodrine, we observed lower levels of aldose reductase, tumor necrosis factor-α, and sorbitol, but higher levels of hexokinase, 5'-adenosine monophosphate-activated protein kinase-alpha, adenosine 5´-triphosphate, peroxisome proliferator-activated receptordelta, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, superoxide dismutase, and catalase.
The ameliorating effects of midodrine on cataracts in the OLETF obesity rat model are exerted via the following three mechanisms: direct inhibition of the biosynthesis of sorbitol, which causes cataracts; reduction of reactive oxygen species and inflammation; and (3) stimulation of normal aerobic glycolysis.
由于缺乏运动和西式饮食的增加,肥胖的患病率正在增加,导致各种并发症,包括眼科疾病。例如,肥胖与白内障的发生有关。
为了阐明 α1-肾上腺素受体激动剂米多君在肥胖引起的白内障中的作用和机制,我们在肥胖大鼠模型——大冢长寿命非肥胖糖尿病(OLETF)大鼠中进行了各种分析实验。
米多君可预防 OLETF 大鼠白内障的发生并改善晶状体清晰度。在用米多君治疗的 OLETF 大鼠晶状体中,我们观察到醛糖还原酶、肿瘤坏死因子-α 和山梨醇的水平降低,而己糖激酶、5'-腺嘌呤单磷酸激活蛋白激酶-α、三磷酸腺苷、过氧化物酶体增殖物激活受体 δ、过氧化物酶体增殖物激活受体 γ 共激活剂 1-α、超氧化物歧化酶和过氧化氢酶的水平升高。
米多君对 OLETF 肥胖大鼠模型白内障的改善作用是通过以下三种机制实现的:直接抑制导致白内障的山梨醇的生物合成;减少活性氧和炎症;和(3)刺激正常的有氧糖酵解。